Biocon’s Yesafili has FDA approval, but these new switching results may decide whether eye specialists embrace it
Biocon’s new Yesafili studies add switching and subgroup evidence ahead of a planned U.S. launch in the competitive aflibercept market.
Pharma & Biotech